Detalhe da pesquisa
1.
Ethical use of off-label disease-modifying therapies for multiple sclerosis.
Mult Scler
; 27(9): 1403-1410, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34304636
2.
World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application.
Mult Scler
; 26(2): 153-158, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31944872
3.
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.
Mult Scler
; 26(14): 1816-1821, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33174475
4.
Patient level dataset to study the effect of COVID-19 in people with Multiple Sclerosis.
Sci Data
; 11(1): 149, 2024 Jan 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38297080
5.
Global synergistic actions to improve brain health for human development.
Nat Rev Neurol
; 19(6): 371-383, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37208496
6.
Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.
Mult Scler
; 18(11): 1534-40, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22917690
7.
The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions.
Mult Scler Relat Disord
; 61: 103757, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35367873
8.
World Brain Day 2021: a call to stop multiple sclerosis.
Lancet Neurol
; 20(8): 597-598, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34166643
9.
Health-care disparities for people with multiple sclerosis.
Lancet Neurol
; 19(3): 207-208, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32085833